Email this page: News Release
TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by TG Therapeutics, Inc. for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps TG Therapeutics, Inc. prevent automated submissions.